#SkinnyTok banned: A look a viral weight loss hacks on TikTok and why you should avoid them
According to USA Today, TikTok recently put a ban on the hashtag #SkinnyTok after multiple warnings and public outrage regarding the trend promotion of highly dangerous body standards and extreme weight loss.
This hasn't happened for the first time. In September last year, Liv Schmidt got banned after building her platform around weight loss and thinness.
From #SkinnyTok to extreme diet challenges, social media platforms, such as TikTok, are filled with millions of videos centered around health and wellness.
Viewed by a large number of users, these videos boast about how people can shed weight in less amount of time. What remains concerning is that such trends fail to have any scientific backing and often can end up posing serious health risks to individuals.
Also read: Influencer Erika Cramer's Instagram account suspended due to shocking reason: 'I've been accused...' Popular weight loss hacks on TikTok Ozempic medication
Although a diabetes medication, Ozempic is misused by individuals and promoted as a fast weight-loss solution. But experts suggest that it can ultimately lead to serious side effects, such as nausea, pancreatitis, and thyroid tumors, according to digital magazine Sugbo.ph. Coffee and lemonade
Having a mix of coffee and lemon juice can help in suppressing appetite, according to some social media influencers. However, they fail to inform their fans that it can ultimately lead to dehydration and even stomach ulcers in some cases. Rice water detox
Another popular health trend advises consuming rice water as a metabolism booster. This is being promoted without any scientific evidence supporting the claim. Extreme fasting
Fasting for longer periods can result in muscle loss and deficiency of nutrients in the body, according to experts. FAQs: 1. Does Ozempic help in weight loss?
According to the Cleveland Clinic, taking Ozempic or similar medications makes more GLP-1 in the body, which decreases appetite and makes people feel fuller. 2. What is #SkinnyTok?
This was a popular hashtag on TikTok, which promoted content which advises people on how to be skinnier. 3. What's the best method for weight loss?
There are several authentic ways advised by experts to lose weight, with sustainable lifestyle changes being a key focus.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Print
2 hours ago
- The Print
‘Fat-shamers are now Ozempic-shamers' — new book takes on India's weight-loss obsession
It was a power-packed panel: Minister of State Jitendra Singh, actor Sharmila Tagore, and HT Media chairperson Shobhana Bhartia shared the stage alongside the two authors and Sanghvi. 'Will you be listed among the quacks – the dieticians and gym trainers who masquerade as weight-loss experts?' journalist and columnist Vir Sanghvi asked Mithal, half-jokingly. New Delhi: At the launch of leading endocrinologist Ambrish Mithal's book on obesity, co-authored with journalist Shivam Vij, the discussion turned to India's cultural obsession with weight loss and the science behind the drugs that have everyone in a chokehold. But the question that kicked off the event at Delhi's ITC Maurya last week captured both the uncertainty and the social media debates swirling around those promoting such drugs. Mithal and Vij's book — The Weight Loss Revolution: Weight Loss Drugs and How to Use Them, published by Juggernaut Books — describes itself as the authoritative work on Ozempic, Mounjaro and other GLP-1 drugs. Also read: Desperate Indians want Ozempic on prescription. Huge shift from traditional drugs, say doctors The science behind the 'revolution' While working on the book, Mithal sought to confront a hydra-headed demon: misinformation. The rise of GLP-1 drugs is linked to the increase in health-related conversation, media consumption, and a society in which being thin is the perennial aspiration. As a result, it's been written and talked about tremendously. 'The media either takes it to one extreme or another,' Mithal said. 'Nearly every two weeks, The New York Times has an article saying that this is the answer to the world's problems. Then there are those who say this is a marketing gimmick. As usual, the answer lies somewhere in between.' The book's genesis lay in Mithal's desire to explain the science behind what has been described as 'a revolution' in the weight loss world. Vij, Mithal's co-writer and first obesity patient to take semaglutide — the active ingredient in Ozempic and Wegovy — said he lost 15 kgs over the past 15 months. Now, the endocrinologist has one hundred patients on Wegovy, over 500 on Mounjaro (tirzepatide), and thousands on Rybelsus. These drugs were originally prescribed for diabetes. However, half of Mithal's patients want to use the drug to lose weight. 'Over the years, other than lifestyle changes and invasive bariatric surgery, all other methods to treat obesity have fallen off,' said Mithal. Also read: I was a pregnant penguin, see my before-after pics. 66-yr-old's Ozempic to Mounjaro journey Standing up to Ozempic-shamers GLP-1 drugs exist in a strange, inchoate space. There's covert acceptance, with leading celebrities taking Ozempic and the easy availability of the drug. But for the most part, there's reluctance in terms of public acknowledgment. Moreover, its usage is met with scepticism. As Vij noted, a layer of shame surrounds those who have taken it –– because they supposedly haven't 'put in the work.' 'Yesterday's fat-shamers are today's Ozempic-shamers,' he said. 'They're not happy either way. When you're fat, they're unhappy and when you're thin, they're unhappy.' The book features interviews with nine of Mithal's patients. One of them, a 26-year-old woman, gained weight after an accident at the age of 18. She was unable to lose weight through traditional methods. Other than delving into the science, the book also appears to lift some of the stigma around the drugs –– facilitating widespread, public acceptance. Actor Sharmila Tagore, who made it to the event via three modes of transport courtesy rain and the ensuing traffic, said that having spent her life in front of the camera, 'she understands society's obsession with bodies.' That's why this book comes at a critical time, as these drugs are projected to fundamentally alter this obsession. 'In a few years, everybody will be on it and everybody will be thin. That's my prediction,' said Vij. (Edited by Prashant)
Time of India
5 hours ago
- Time of India
After rabbits with tentacles the rise of hairless zombie squirrels with oozing flesh scares US neighbourhoods: See pics
Just when Colorado residents were still reeling from viral photos of rabbits sporting black horn-like growths, a new creepy critter has entered the chat – squirrels with bulging, hairless tumours that make them look straight out of a zombie flick. Sightings have popped up in states like Maine and even across Canada, with locals branding the creatures 'zombie squirrels.' What is really happening to these squirrels? Experts have explained that the disturbing growths are likely a result of a condition called squirrel fibromatosis, a poxvirus in the same family as the infamous myxoma virus that wreaks havoc on rabbits. Some have speculated about squirrelpox, a virus more commonly associated with British red squirrel declines, but that option seems less likely in the U.S. Despite the nightmare aesthetics, fibromatosis is not the squirrel apocalypse. The disease is common, usually non-lethal, and the tumours typically shrink on their own after a few weeks or months. It spreads through close squirrel-to-squirrel contact, shared feeding spots, and insects like fleas and mosquitoes. Wildlife officials say do not panic Shevenell Webb of Maine's Department of Inland Fisheries and Wildlife has reassured residents that 'zombie squirrels' are scarier to look at than to live around. Neither fibromatosis nor squirrelpox pose risks to humans, pets, or birds. The best advice, Webb said, is to simply leave the squirrels alone and let nature take its course. We had rabbits growing spikes last week and we have 'Zombie Squirrels' this week. Leporipoxvirus is what it's called. Rabbit tentacle horror show The rise of 'zombie squirrels' comes hot on the heels of viral rabbit sightings in Colorado that looked like something from a horror B-movie. Locals reported rabbits with black tentacle-like growths sprouting from their faces, sparking online comparisons to 'aliens' and 'Frankenstein bunnies.' Wildlife officials confirmed those rabbits are suffering from Shope papillomavirus (SPV), a rabbit-only infection that causes wart-like tumours around the face and head. Much like fibromatosis, it is spread by biting insects, cannot infect humans or pets, and usually does not harm the rabbit unless it interferes with eating or vision. Nature is out-creeping the internet Between tentacle bunnies and tumour-ridden squirrels, it feels like North America is in its very own low-budget horror trilogy. The reality, though, is that these viral animal oddities are age-old wildlife diseases, not signs of an impending zombie apocalypse. Still, try explaining that to TikTok.
Time of India
5 hours ago
- Time of India
What other health conditions are weight-loss drugs being used and tested for?
Bengaluru: Novo Nordisk 's weight-loss treatment Wegovy gained U.S. approval to treat a progressive liver condition on Friday, as the Danish drugmaker looks to boost sales and widen insurance coverage. Eli Lilly's blockbuster diabetes drug Mounjaro and related weight-loss therapy Zepbound, and Novo's rival medicines Ozempic and Wegovy brought in combined sales of over $40 billion last year, which is expected to rise to $60 billion in 2025. Here are some of the other conditions the drugs are being used and tested for: Alcohol addiction A study conducted by the University of Copenhagen's Psychiatric Centre Rigshospitalet is investigating whether semaglutide - the main ingredient in Wegovy and Ozempic - can help reduce alcohol intake in 108 patients diagnosed with alcohol use disorder and obesity . Alzheimer's disease Novo Nordisk is testing semaglutide in a late-stage trial in patients with early Alzheimer's disease. The study, which will enroll 1,840 patients, could have an initial data readout as early as later this year. Cardiovascular disease Eli Lilly was testing tirzepatide - the main ingredient in Mounjaro and Zepbound - for patients with heart failure and obesity. Lilly had said it would enroll about 700 people in the study, but the company said in May that it has withdrawn its U.S. application for heart failure approval. Novo won the U.S. Food and Drug Administration's approval in 2024 to use Wegovy to reduce the risk of cardiovascular death, heart attack and stroke in overweight or obese adults without diabetes. The European Medicines Agency backed the use of Novo's semaglutide to help ease heart failure symptoms in people with obesity in September 2024. Chronic kidney disease Novo's Ozempic is approved in the United States for reducing the risk of kidney failure and disease progression as well as the risk of death due to heart problems in diabetes patients with chronic kidney disease. Lilly's tirzepatide is being evaluated in a mid-stage study of patients with chronic kidney disease and obesity. Lilly plans to enroll up to 140 participants with the study expected to be completed next year. Liver disease Novo's Wegovy in August became the first GLP-1 therapy approved in the U.S. to treat adults with metabolic dysfunction-associated steatohepatitis, or MASH, based on results from the first part of its late-stage trial. Results from the second part, with about 1,200 patients, is expected in 2029. Lilly's tirzepatide in February helped up to 74% of patients achieve absence of MASH with no worsening of liver scarring at 52 weeks, compared with 13% of patients on placebo, in a mid-stage trial. Neurological disorders Researchers at the Danish Headache Center are testing semaglutide along with a very low calorie diet as a treatment for new-onset idiopathic intracranial hypertension, a condition associated with obesity in which blood pressure inside the head rises. The study has enrolled about 50 patients and is expected to complete in October 2025. Sleep apnea Zepbound was approved by the U.S. Food and Drug Administration for obstructive sleep apnea in December 2024, making it the first drug to directly treat patients with the common disorder that causes breathing disruption while sleeping.
